立方制药子公司取得一项药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Loxoprofen Sodium Oral Solution, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hefei Chengzhi Biopharmaceutical Co., Ltd., is responsible for the newly approved Loxoprofen Sodium Oral Solution [1] - Loxoprofen Sodium is classified as a non-steroidal anti-inflammatory drug (NSAID) with strong analgesic, anti-inflammatory, and antipyretic properties, particularly noted for its potent analgesic effects [1]